A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP

NCT07702851 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: Polatuzumab vedotin, Glofitamab

Sponsor

Yonsei University